Investigates genetic factors affecting treatment response in chronic hepatitis C, suggesting implications for personalized medicine.
The study investigates how genetic variability in interferon‑stimulated genes (ISGs), together with well‑known polymorphisms in IL‑28B, influences treatment response in patients with chronic hepatitis C undergoing pegylated‑interferon plus ribavirin therapy. A cohort of 285 patients was genotyped for 63 SNPs, revealing that variants in OASL and IFIT1 significantly enhance the predictive value of IL‑28B, particularly in individuals infected with HCV genotype 1. These findings contribute to the advancement of personalized medicine by identifying genetic combinations with strong prognostic value for optimizing therapeutic decision‑making in chronic hepatitis C.
No takes yet. Share an insight, caveat, or question.
Lopez-Rodriguez et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: